MX2019002271A - Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. - Google Patents
Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.Info
- Publication number
- MX2019002271A MX2019002271A MX2019002271A MX2019002271A MX2019002271A MX 2019002271 A MX2019002271 A MX 2019002271A MX 2019002271 A MX2019002271 A MX 2019002271A MX 2019002271 A MX2019002271 A MX 2019002271A MX 2019002271 A MX2019002271 A MX 2019002271A
- Authority
- MX
- Mexico
- Prior art keywords
- rnai constructs
- methods
- inhibiting
- expression
- asgr1 expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380216P | 2016-08-26 | 2016-08-26 | |
| PCT/US2017/048757 WO2018039647A1 (en) | 2016-08-26 | 2017-08-25 | Rnai constructs for inhibiting asgr1 expression and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002271A true MX2019002271A (es) | 2019-06-20 |
Family
ID=59846644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002271A MX2019002271A (es) | 2016-08-26 | 2017-08-25 | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. |
| MX2024009873A MX2024009873A (es) | 2016-08-26 | 2019-02-25 | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009873A MX2024009873A (es) | 2016-08-26 | 2019-02-25 | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10870856B2 (https=) |
| EP (1) | EP3504333A1 (https=) |
| JP (3) | JP7082610B2 (https=) |
| AR (1) | AR110629A1 (https=) |
| AU (2) | AU2017315952B2 (https=) |
| CA (2) | CA3277899A1 (https=) |
| MX (2) | MX2019002271A (https=) |
| TW (1) | TW201823461A (https=) |
| UY (1) | UY37376A (https=) |
| WO (1) | WO2018039647A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| FI3661562T3 (fi) * | 2017-08-04 | 2024-12-09 | Amgen Inc | Cys-mab:ien konjugointimenetelmä |
| US11492624B2 (en) | 2017-10-17 | 2022-11-08 | Arrowheads Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 |
| AU2018360697A1 (en) * | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| CN112424371B (zh) | 2018-06-07 | 2024-06-28 | 美国安进公司 | 蛋白质-多核苷酸缀合物的检测测定 |
| EP3894554A1 (en) * | 2018-12-10 | 2021-10-20 | Amgen Inc. | Chemically-modified rnai constructs and uses thereof |
| TW202111124A (zh) * | 2019-05-30 | 2021-03-16 | 美商安進公司 | 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法 |
| AU2020301419B2 (en) | 2019-06-25 | 2026-03-19 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
| EP4126967A1 (en) | 2020-03-23 | 2023-02-08 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| CN111705063B (zh) * | 2020-06-02 | 2023-08-08 | 成都中科奥格生物科技有限公司 | Asgr1突变基因及其在制备哺乳动物肝损伤敏感模型中的应用 |
| WO2024046297A1 (zh) * | 2022-09-02 | 2024-03-07 | 北京福元医药股份有限公司 | 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途 |
| WO2025231448A2 (en) * | 2024-05-03 | 2025-11-06 | University Of Massachusetts | Oligonucleotides targeting myostatin (mstn) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003093449A2 (en) | 2002-05-06 | 2003-11-13 | Nucleonics, Inc. | Methods for delivery of nucleic acids |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| DK1620544T3 (en) | 2003-04-17 | 2019-01-14 | Alnylam Pharmaceuticals Inc | MODIFIED iRNA AGENTS |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| EP2386316B1 (en) * | 2004-06-10 | 2018-02-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN1300312C (zh) | 2004-08-23 | 2007-02-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途 |
| KR101270829B1 (ko) * | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| US20130024961A1 (en) | 2009-12-01 | 2013-01-24 | Christopher Burlak | Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs |
| KR101870915B1 (ko) * | 2011-04-08 | 2018-06-25 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| EP3286318A2 (en) * | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
-
2017
- 2017-08-24 UY UY0001037376A patent/UY37376A/es not_active Application Discontinuation
- 2017-08-25 WO PCT/US2017/048757 patent/WO2018039647A1/en not_active Ceased
- 2017-08-25 US US16/328,221 patent/US10870856B2/en active Active
- 2017-08-25 EP EP17764943.1A patent/EP3504333A1/en active Pending
- 2017-08-25 CA CA3277899A patent/CA3277899A1/en active Pending
- 2017-08-25 MX MX2019002271A patent/MX2019002271A/es unknown
- 2017-08-25 AU AU2017315952A patent/AU2017315952B2/en active Active
- 2017-08-25 JP JP2019511384A patent/JP7082610B2/ja active Active
- 2017-08-25 CA CA3034463A patent/CA3034463C/en active Active
- 2017-08-28 AR ARP170102382A patent/AR110629A1/es unknown
- 2017-08-28 TW TW106129226A patent/TW201823461A/zh unknown
-
2019
- 2019-02-25 MX MX2024009873A patent/MX2024009873A/es unknown
-
2020
- 2020-10-26 US US17/080,771 patent/US11732266B2/en active Active
-
2022
- 2022-02-16 JP JP2022022163A patent/JP7472180B2/ja active Active
-
2024
- 2024-01-04 JP JP2024000208A patent/JP2024019733A/ja active Pending
- 2024-02-29 AU AU2024201349A patent/AU2024201349A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018039647A1 (en) | 2018-03-01 |
| JP2019524151A (ja) | 2019-09-05 |
| JP7472180B2 (ja) | 2024-04-22 |
| JP2024019733A (ja) | 2024-02-09 |
| CA3277899A1 (en) | 2026-03-02 |
| MX2024009873A (es) | 2024-08-20 |
| EP3504333A1 (en) | 2019-07-03 |
| TW201823461A (zh) | 2018-07-01 |
| JP2022060357A (ja) | 2022-04-14 |
| CA3034463C (en) | 2025-09-16 |
| AR110629A1 (es) | 2019-04-17 |
| US11732266B2 (en) | 2023-08-22 |
| US20190309306A1 (en) | 2019-10-10 |
| AU2024201349A1 (en) | 2024-04-11 |
| CA3034463A1 (en) | 2018-03-01 |
| AU2017315952A1 (en) | 2019-03-14 |
| UY37376A (es) | 2018-03-23 |
| US10870856B2 (en) | 2020-12-22 |
| AU2017315952B2 (en) | 2023-11-30 |
| US20210108212A1 (en) | 2021-04-15 |
| JP7082610B2 (ja) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002271A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
| CL2023002358A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y sus métodos de uso | |
| JOP20200115A1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| CL2023002870A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso | |
| CL2021001489A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos | |
| MX2024008022A (es) | Composiciones y kits para el tratamiento de la hemofilia a o b. | |
| PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| MX2016015126A (es) | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. | |
| UY35582A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| CL2022003369A1 (es) | Constructos de arni para inhibir la expresión de hsd17b13 y métodos de uso de los mismos | |
| CL2021003169A1 (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
| CL2024001214A1 (es) | Constructos de arni para inhibir la expresión de gpam y métodos de uso. | |
| HK1241287A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | |
| CL2017002646A1 (es) | Composiciones de arni de serpina1 y sus métodos de uso (divisional de solicitud n° 3441-2015). | |
| PY1421149A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO. | |
| CR20150644A (es) | Composiciones de arni de serapina 1 y sus métodos de uso |